AAAAAA

   
Results: 1-25 | 26-41
Results: 1-25/41
TREATMENT OF AIDS-RELATED NON-HODGKINS-LYMPHOMA WITH CHEMOTHERAPY (CNOP) AND R-HN-G-CSF - CLINICAL OUTCOME AND EFFECT ON HIV-1 VIRAL LOAD
Authors: KERSTEN MJ VERDUYN TJ REISS P EVERS LM DEWOLF F VANOERS MHJ
Citation: Mj. Kersten et al., TREATMENT OF AIDS-RELATED NON-HODGKINS-LYMPHOMA WITH CHEMOTHERAPY (CNOP) AND R-HN-G-CSF - CLINICAL OUTCOME AND EFFECT ON HIV-1 VIRAL LOAD, Annals of oncology, 9(10), 1998, pp. 1135-1138
CELLULAR PROVIRAL HIV TYPE-1 DNA LOAD PERSISTS AFTER LONG-TERM RT-INHIBITOR THERAPY IN HIV TYPE-1 INFECTED PERSONS
Authors: BRUISTEN SM REISS P LOELIGER AE VANSWIETEN P SCHUURMAN R BOUCHER CAB WEVERLING GJ HUISMAN JG
Citation: Sm. Bruisten et al., CELLULAR PROVIRAL HIV TYPE-1 DNA LOAD PERSISTS AFTER LONG-TERM RT-INHIBITOR THERAPY IN HIV TYPE-1 INFECTED PERSONS, AIDS research and human retroviruses, 14(12), 1998, pp. 1053-1058
INDUCTION-MAINTENANCE ANTIRETROVIRAL THERAPY - PROOF-OF-CONCEPT
Authors: HALL DB MONTANER JGS REISS P COOPER D VELLA S DOHNANYI C MYERS M LANGE J CONWAY B
Citation: Db. Hall et al., INDUCTION-MAINTENANCE ANTIRETROVIRAL THERAPY - PROOF-OF-CONCEPT, AIDS, 12(7), 1998, pp. 41-44
REGRESSION OF AIDS-RELATED KAPOSIS-SARCOMA ASSOCIATED WITH CLEARANCE OF HUMAN-HERPESVIRUS-8 FROM PERIPHERAL-BLOOD MONONUCLEAR-CELLS FOLLOWING INITIATION OF ANTIRETROVIRAL THERAPY
Authors: WIT FWNM SOL CJA RENWICK N ROOS MTL PALS ST VANLEEUWEN R GOUDSMIT J REISS P
Citation: Fwnm. Wit et al., REGRESSION OF AIDS-RELATED KAPOSIS-SARCOMA ASSOCIATED WITH CLEARANCE OF HUMAN-HERPESVIRUS-8 FROM PERIPHERAL-BLOOD MONONUCLEAR-CELLS FOLLOWING INITIATION OF ANTIRETROVIRAL THERAPY, AIDS, 12(2), 1998, pp. 218-219
COMPARISON OF THE PLASMA PHARMACOKINETICS AND RENAL CLEARANCE OF DIDANOSINE DURING ONCE AND TWICE-DAILY DOSING IN HIV-1-INFECTED INDIVIDUALS
Authors: HOETELMANS RMW VANHEESWIJK RPG PROFIJT M MULDER JW MEENHORST PL LANGE JMA REISS P BEIJNEN JH
Citation: Rmw. Hoetelmans et al., COMPARISON OF THE PLASMA PHARMACOKINETICS AND RENAL CLEARANCE OF DIDANOSINE DURING ONCE AND TWICE-DAILY DOSING IN HIV-1-INFECTED INDIVIDUALS, AIDS, 12(17), 1998, pp. 211-216
ESTIMATES OF THE VIROLOGICAL BENEFIT OF ANTIRETROVIRAL THERAPY ARE BOTH ASSAY-DEPENDENT AND ANALYSIS-DEPENDENT
Authors: RAE S RABOUD JM CONWAY B REISS P VELLA S COOPER D LANGE J HARRIS M WAINBERG MA ROBINSON P MYERS M HALL D MONTANER JSG
Citation: S. Rae et al., ESTIMATES OF THE VIROLOGICAL BENEFIT OF ANTIRETROVIRAL THERAPY ARE BOTH ASSAY-DEPENDENT AND ANALYSIS-DEPENDENT, AIDS, 12(16), 1998, pp. 2185-2192
SUPPRESSION OF PLASMA VIRAL LOAD BELOW 20 COPIES ML IS REQUIRED TO ACHIEVE A LONG-TERM RESPONSE TO THERAPY/
Authors: RABOUD JM MONTANER JSG CONWAY B RAE S REISS P VELLA S COOPER D LANGE O HARRIS M WAINBERG MA ROBINSON P MYERS M HALL D
Citation: Jm. Raboud et al., SUPPRESSION OF PLASMA VIRAL LOAD BELOW 20 COPIES ML IS REQUIRED TO ACHIEVE A LONG-TERM RESPONSE TO THERAPY/, AIDS, 12(13), 1998, pp. 1619-1624
LONG-TERM FOLLOW-UP OF RANDOMIZED TRIALS OF IMMEDIATE VERSUS DEFERREDZIDOVUDINE IN SYMPTOM-FREE HIV-INFECTION
Authors: ABOULKER JP BABIKER AG CLUMECK N COOPER DA DARBYSHIRE JH DORMONT J GATELL J GOEBEL F LAURIAN Y MANNUCCI P MATHIESEN L PETO TEA REISS P SANDSTROM E SAVIDGE G SELIGMANN M SMITH D STINGL G VEENSTRA J WELLER IVD YEO J LAFON E MCCORMACK S SWART AM WITHNALL R
Citation: Jp. Aboulker et al., LONG-TERM FOLLOW-UP OF RANDOMIZED TRIALS OF IMMEDIATE VERSUS DEFERREDZIDOVUDINE IN SYMPTOM-FREE HIV-INFECTION, AIDS, 12(11), 1998, pp. 1259-1265
IMPROVEMENT OF CHRONIC DIARRHEA IN PATIENTS WITH ADVANCED HIV-1 INFECTION DURING POTENT ANTIRETROVIRAL THERAPY
Authors: FOUDRAINE NA WEVERLING GJ VANGOOL T ROOS MTL DEWOLF F KOOPMANS PP VANDENBROEK PJ MEENHORST PL VANLEEUWEN R LANGE JMA REISS P
Citation: Na. Foudraine et al., IMPROVEMENT OF CHRONIC DIARRHEA IN PATIENTS WITH ADVANCED HIV-1 INFECTION DURING POTENT ANTIRETROVIRAL THERAPY, AIDS, 12(1), 1998, pp. 35-41
MAINTENANCE THERAPY AFTER QUADRUPLE INDUCTION THERAPY IN HIV-1-INFECTED INDIVIDUALS - AMSTERDAM DURATION OF ANTIRETROVIRAL MEDICATION (ADAM) STUDY
Authors: REIJERS MHE WEVERLING GJ JURRIAANS S WIT FWNM WEIGEL HM TENKATE RW MULDER JW FRISSEN PHJ VANLEEUWEN R REISS P SCHUITEMAKER H DEWOLF F LANGE JMA
Citation: Mhe. Reijers et al., MAINTENANCE THERAPY AFTER QUADRUPLE INDUCTION THERAPY IN HIV-1-INFECTED INDIVIDUALS - AMSTERDAM DURATION OF ANTIRETROVIRAL MEDICATION (ADAM) STUDY, Lancet, 352(9123), 1998, pp. 185-190
A RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING COMBINATIONS OF NEVIRAPINE, DIDANOSINE, AND ZIDOVUDINE FOR HIV-INFECTED PATIENTS - THE INCAS TRIAL
Authors: MONTANER JSG REISS P COOPER D VELLA S HARRIS M CONWAY B WAINBERG MA SMITH D ROBINSON P HALL D MYERS M LANGE JMA
Citation: Jsg. Montaner et al., A RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING COMBINATIONS OF NEVIRAPINE, DIDANOSINE, AND ZIDOVUDINE FOR HIV-INFECTED PATIENTS - THE INCAS TRIAL, JAMA, the journal of the American Medical Association, 279(12), 1998, pp. 930-937
EFFECTS OF PROTEASE INHIBITORS ON THE COURSE OF CMV RETINITIS IN RELATION TO CD4-RESPONSES IN HIV+ PATIENTS( LYMPHOCYTE)
Authors: VANDENHORN GJ MEENKEN C DANNER SA REISS P DESMET MD
Citation: Gj. Vandenhorn et al., EFFECTS OF PROTEASE INHIBITORS ON THE COURSE OF CMV RETINITIS IN RELATION TO CD4-RESPONSES IN HIV+ PATIENTS( LYMPHOCYTE), British journal of ophthalmology, 82(9), 1998, pp. 988-990
PATTERNS OF T-CELL REPOPULATION, VIRUS LOAD REDUCTION, AND RESTORATION OF T-CELL FUNCTION IN HIV-INFECTED PERSONS DURING THERAPY WITH DIFFERENT ANTIRETROVIRAL AGENTS
Authors: PAKKER NG ROOS MTL VANLEEUWEN R DEJONG MD KOOT M REISS P LANGE JMA MIEDEMA F DANNER SA SCHELLEKENS PTA
Citation: Ng. Pakker et al., PATTERNS OF T-CELL REPOPULATION, VIRUS LOAD REDUCTION, AND RESTORATION OF T-CELL FUNCTION IN HIV-INFECTED PERSONS DURING THERAPY WITH DIFFERENT ANTIRETROVIRAL AGENTS, Journal of acquired immune deficiency syndromes and human retrovirology, 16(5), 1997, pp. 318-326
REGIONAL DIFFERENCES IN USE OF ANTIRETROVIRAL AGENTS AND PRIMARY PROPHYLAXIS IN 3122 EUROPEAN HIV-INFECTED PATIENTS
Authors: LUNDGREN JD PHILLIPS AN VELLA S KATLAMA C LEDERGERBER B JOHNSON AM REISS P GATELL J CLUMECK N DIETRICH M BENFIELD TL NIELSEN JO PEDERSEN C
Citation: Jd. Lundgren et al., REGIONAL DIFFERENCES IN USE OF ANTIRETROVIRAL AGENTS AND PRIMARY PROPHYLAXIS IN 3122 EUROPEAN HIV-INFECTED PATIENTS, Journal of acquired immune deficiency syndromes and human retrovirology, 16(3), 1997, pp. 153-160
EXPRESSION OF GRANZYME-B BY CYTOTOXIC T-LYMPHOCYTES IN THE LYMPH-NODES OF HIV-INFECTED PATIENTS
Authors: KOOPMAN G WEVER PC RAMKEMA MD BELLOT F REISS P KEEHNEN RMJ TENBERGE IJM PALS ST
Citation: G. Koopman et al., EXPRESSION OF GRANZYME-B BY CYTOTOXIC T-LYMPHOCYTES IN THE LYMPH-NODES OF HIV-INFECTED PATIENTS, AIDS research and human retroviruses, 13(3), 1997, pp. 227-233
LIPOSOMAL AMPHOTERICIN-B (AMBISOME) COMPARED WITH AMPHOTERICIN-B BOTHFOLLOWED BY ORAL FLUCONAZOLE IN THE TREATMENT OF AIDS-ASSOCIATED CRYPTOCOCCAL MENINGITIS
Authors: LEENDERS ACAP REISS P PORTEGIES P CLEZY K HOP WCJ HOY J BORLEFFS JCC ALLWORTH T KAUFFMANN RH JONES P KROON FP VERBRUGH HA DEMARIE S
Citation: Acap. Leenders et al., LIPOSOMAL AMPHOTERICIN-B (AMBISOME) COMPARED WITH AMPHOTERICIN-B BOTHFOLLOWED BY ORAL FLUCONAZOLE IN THE TREATMENT OF AIDS-ASSOCIATED CRYPTOCOCCAL MENINGITIS, AIDS, 11(12), 1997, pp. 1463-1471
HIV-1 VIRAL LOAD, PHENOTYPE, AND RESISTANCE IN A SUBSET OF DRUG-NAIVEPARTICIPANTS FROM THE DELTA-TRIAL
Authors: BRUNVEZINET F BOUCHER C LOVEDAY C DESCAMPS D FAUVEAU V IZOPET J JEFFRIES D KAYE S KRZYANOWSKI C NUNN A SCHUURMAN R SEIGNEURIN JM TAMALET C TEDDER R WEBER J WEVERLING GJ ABER V ABOULKER JP BABIKER AG BRAGMAN K BRECKENRIDGE AM CARBON C CHARREAU I CHENE G COLLIS P COOPER D DARBYSHIRE JH DORMONT J FIDDIAN P FLEPP M GAZZARD B GOEBEL FD HOOKER M LANGE J LUTHY R PETO TEA REISS P SELIGMANN M STONE AB THOMIS J VELLA S WALCKENAER G WARRELL D WELLER IVD WILBER R YENI P YEO J WITHNALL R BABIKER A BLOCH J POUCHER C DARBYSHIRE J GOUDSMIT J HURAUX JM VANDERNOORDAA J WEISS R WEVERLING G
Citation: F. Brunvezinet et al., HIV-1 VIRAL LOAD, PHENOTYPE, AND RESISTANCE IN A SUBSET OF DRUG-NAIVEPARTICIPANTS FROM THE DELTA-TRIAL, Lancet, 350(9083), 1997, pp. 983-990
RANDOMIZED TRIAL OF ADDITION OF LAMIVUDINE OR LAMIVUDINE PLUS LOVIRIDE TO ZIDOVUDINE-CONTAINING REGIMENS FOR PATIENTS WITH HIV-1 INFECTION - THE CAESAR TRIAL
Authors: COOPER DA KATLAMA C MONTANER J COLLIS PJ ANTUNES F ATKINSON M CLARK A CLUMECK N COLLIS P GAZZARD B GERSTOFT J GOH L HILL A KORSIA S LANGE J MCCALLUM L MCDADE H MALLOLAS J MORONI M NORKRANS G OPRAVIL M REISS P ROZENBAUM W SCOTT J SMITH D STASZEWSKI S STOFFELS P
Citation: Da. Cooper et al., RANDOMIZED TRIAL OF ADDITION OF LAMIVUDINE OR LAMIVUDINE PLUS LOVIRIDE TO ZIDOVUDINE-CONTAINING REGIMENS FOR PATIENTS WITH HIV-1 INFECTION - THE CAESAR TRIAL, Lancet, 349(9063), 1997, pp. 1413-1421
HIGH-DOSE INTERFERON-ALPHA-2A EXERTS POTENT ACTIVITY AGAINST HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 NOT ASSOCIATED WITH ANTITUMOR-ACTIVITY IN SUBJECTS WITH KAPOSIS-SARCOMA
Authors: FRISSEN PHJ DEWOLF F REISS P BAKKER PJM VEENHOF CHN DANNER SA GOUDSMIT J LANGE JMA
Citation: Phj. Frissen et al., HIGH-DOSE INTERFERON-ALPHA-2A EXERTS POTENT ACTIVITY AGAINST HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 NOT ASSOCIATED WITH ANTITUMOR-ACTIVITY IN SUBJECTS WITH KAPOSIS-SARCOMA, The Journal of infectious diseases, 176(3), 1997, pp. 811-814
ADDITIVE OR SEQUENTIAL NUCLEOSIDE ANALOG THERAPY COMPARED WITH CONTINUED ZIDOVUDINE MONOTHERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS WITH ADVANCED DISEASE DOES NOT PROLONG SURVIVAL - AN OBSERVATIONAL STUDY
Authors: VANLEEUWEN R BONSEL GJ REISS P DANNER SA LANGE JMA
Citation: R. Vanleeuwen et al., ADDITIVE OR SEQUENTIAL NUCLEOSIDE ANALOG THERAPY COMPARED WITH CONTINUED ZIDOVUDINE MONOTHERAPY IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS WITH ADVANCED DISEASE DOES NOT PROLONG SURVIVAL - AN OBSERVATIONAL STUDY, The Journal of infectious diseases, 175(6), 1997, pp. 1344-1351
HIGH-DOSE NEVIRAPINE IN PREVIOUSLY UNTREATED HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED PERSONS DOES NOT RESULT IN SUSTAINED SUPPRESSION OF VIRAL REPLICATION
Authors: DEJONG MD VELLA S CARR A BOUCHER CAB IMRIE A FRENCH M HOY J SORICE S PAULUZZI S CHIODO F WEVERLING GJ VANDERENDE ME FRISSEN PJ WEIGEL HM KAUFFMANN RH LANGE JMA YOON R MORONI M HOENDERDOS E LEITZ G COOPER DA HALL D REISS P
Citation: Md. Dejong et al., HIGH-DOSE NEVIRAPINE IN PREVIOUSLY UNTREATED HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED PERSONS DOES NOT RESULT IN SUSTAINED SUPPRESSION OF VIRAL REPLICATION, The Journal of infectious diseases, 175(4), 1997, pp. 966-970
SELECTIVE-INHIBITION OF SYNCYTIUM-INDUCING AND NONSYNCYTIUM-INDUCING HIV-1 VARIANTS IN INDIVIDUALS RECEIVING DIDANOSINE OR ZIDOVUDINE, RESPECTIVELY
Authors: VANTWOUT AB RAN LJ DEJONG MD BAKKER M VANLEEUWEN R NOTERMANS DW LOELIGER AE DEWOLF F DANNER SA REISS P BOUCHER CAB LANGE JMA SCHUITEMAKER H
Citation: Ab. Vantwout et al., SELECTIVE-INHIBITION OF SYNCYTIUM-INDUCING AND NONSYNCYTIUM-INDUCING HIV-1 VARIANTS IN INDIVIDUALS RECEIVING DIDANOSINE OR ZIDOVUDINE, RESPECTIVELY, The Journal of clinical investigation, 100(9), 1997, pp. 2325-2332
PYRIMETHAMINE-CLINDAMYCIN VS PYRIMETHAMINE-SULFADIAZINE AS ACUTE AND LONG-TERM THERAPY FOR TOXOPLASMIC ENCEPHALITIS IN PATIENTS WITH AIDS
Authors: KATLAMA C DEWIT S ODOHERTY E VANGLABEKE M CLUMECK N PAYEN MC MATHIESEN L NIELSEN JO PEDERSEN C DUPONT B PIALOUX G JANBON F REYNES J GALLAIS H MARS ME JEANTILS V SCHNEIDER MC AVEROUS V DECAZES JM DOCOLECOMPTE T MODAI J MOLINA JM BLANC A DELFRAISSY JF GUILLEVIN L JARROUSSE B SEHOUANE R TROGOFF B ARMENGAUD M MARCHOU B MEURISSE JJ GENTILINI M GUICHARD A ROGEAUX O LIVROZET JM TOURAINE JL SERENI D ROUSSEAU F PESCE A COULAUD JP DETRUCHIS P FEGUEUX S MASLO C MATHERON S RAFFI F BASSETTI D CANESSA A DELBONO V DELEO P TERRAGNA A ANTINORI A DAMIANO F ORTONA L PALLAVICINI F TAMBURRINI E ANGARANO G CARBONARA S PASTORE G PORTEGIES P REISS P COSTA J MACHADO J MALTEZ F MORGADO A PROENCA R ANTUNES F CARVALHO C DOROANA M DUARTE N ARAUJO C CHAMPALIMAUD JL COSTA J MANSINHO K SEIXAS J LACRUZ J LOPEZALDEGUER J GATELL JM GUELAR A MALLOLAS J MIRO JM ZAMORA L CLOTET B JOU A RAVENTOS A ROMEU J SIRERA G BOLAO F CASANOVA A GUDIOL F PODZAMCZER D GAZAPO E GONZALEZLAHOZ JM BLANCO LM MORENO V POLO R MARTINEZ MC SANZ J VERDEJO J COSIN J MIRALLES P MORENO S PEREZTASCON O HIRSCHEL B PERRIER A RASSAERT C SOMMEREIJNS B UBRICH V BERLUREAU P DORMONT J LEVY JP MEUNIER F MIGNOLET F VANGLABEKE M VANPOTTELSBERGE C
Citation: C. Katlama et al., PYRIMETHAMINE-CLINDAMYCIN VS PYRIMETHAMINE-SULFADIAZINE AS ACUTE AND LONG-TERM THERAPY FOR TOXOPLASMIC ENCEPHALITIS IN PATIENTS WITH AIDS, Clinical infectious diseases, 22(2), 1996, pp. 268-275
THE ALPHA-TRIAL - EUROPEAN AUSTRALIAN RANDOMIZED DOUBLE-BLIND TRIAL OF 2 DOSES OF DIDANOSINE IN ZIDOVUDINE-INTOLERANT PATIENTS WITH SYMPTOMATIC HIV DISEASE/
Authors: CARBON C WARRELL D ABOULKER JP COOPER DA DARBYSHIRE JH DORMONT J FLEPP M LANGE J LEVY JP MATHIESEN L PETO TEA PINCHING AJ REISS P SCHWARTZ D SELIGMANN M STONE A THOMIS J WITHNALL R BARKER S FRISSEN PJ DEJONG MD LOEWENTHAL M TOURNERIE C VALENTINE C ABER V BABIKER AG CHARREAU I THAKRAR B VRAY M LUTHY R
Citation: C. Carbon et al., THE ALPHA-TRIAL - EUROPEAN AUSTRALIAN RANDOMIZED DOUBLE-BLIND TRIAL OF 2 DOSES OF DIDANOSINE IN ZIDOVUDINE-INTOLERANT PATIENTS WITH SYMPTOMATIC HIV DISEASE/, AIDS, 10(8), 1996, pp. 867-880
FUNCTIONAL-CAPACITY OF T-CELLS AND IMMUNOLOGICAL RESPONSE IN NAIVE HIV-1 PATIENTS TREATED WITH COMBINATIONS OF REVERSE-TRANSCRIPTASE INHIBITORS
Authors: PAKKER N KROON E HALL D ROOS M MONTANER JSG COOPER D VELLA S LANGE J KOOT M REISS P
Citation: N. Pakker et al., FUNCTIONAL-CAPACITY OF T-CELLS AND IMMUNOLOGICAL RESPONSE IN NAIVE HIV-1 PATIENTS TREATED WITH COMBINATIONS OF REVERSE-TRANSCRIPTASE INHIBITORS, AIDS, 10, 1996, pp. 21-21
Risultati: 1-25 | 26-41